GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Luoxin Pharmaceutical Group Stock Co Ltd (OTCPK:SLUXY) » Definitions » Revenue

Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Revenue : $646.7 Mil (TTM As of Mar. 2017)


View and export this data going back to 2009. Start your Free Trial

What is Shandong Luoxin Pharmaceutical Group Stock Co Revenue?

Shandong Luoxin Pharmaceutical Group Stock Co's revenue for the three months ended in Mar. 2017 was $174.4 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2017 was $646.7 Mil. Shandong Luoxin Pharmaceutical Group Stock Co's Revenue per Share for the three months ended in Mar. 2017 was $2.86. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2017 was $10.61.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Shandong Luoxin Pharmaceutical Group Stock Co Revenue Historical Data

The historical data trend for Shandong Luoxin Pharmaceutical Group Stock Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Luoxin Pharmaceutical Group Stock Co Revenue Chart

Shandong Luoxin Pharmaceutical Group Stock Co Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 357.51 416.46 447.08 559.98 595.04

Shandong Luoxin Pharmaceutical Group Stock Co Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 143.40 132.22 158.67 181.44 174.40

Competitive Comparison of Shandong Luoxin Pharmaceutical Group Stock Co's Revenue

For the Drug Manufacturers - General subindustry, Shandong Luoxin Pharmaceutical Group Stock Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Luoxin Pharmaceutical Group Stock Co's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Luoxin Pharmaceutical Group Stock Co's Revenue distribution charts can be found below:

* The bar in red indicates where Shandong Luoxin Pharmaceutical Group Stock Co's Revenue falls into.



Shandong Luoxin Pharmaceutical Group Stock Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $646.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Luoxin Pharmaceutical Group Stock Co  (OTCPK:SLUXY) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Shandong Luoxin Pharmaceutical Group Stock Co Revenue Related Terms

Thank you for viewing the detailed overview of Shandong Luoxin Pharmaceutical Group Stock Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Business Description

Traded in Other Exchanges
N/A
Address
Shandong Luoxin Pharmaceutical Group Stock Co Ltd along with its subsidiaries is engaged in the manufacturing and selling of pharmaceutical products. It is involved in the research and development of LXI-15028, a potassium-competitive acid blocker, which is in phase III development for the treatment of reflux esophagitis and other acid-related gastrointestinal diseases; and LXI-15029, an ATP mTOR kinase inhibitor that acts as potent and selective dual inhibitors of mTORC1 and mTORC2 that controls the process of tumor formation and growth. The company mainly operates in the People's Republic of China.

Shandong Luoxin Pharmaceutical Group Stock Co (Shandong Luoxin Pharmaceutical Group Stock Co) Headlines

No Headlines